Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Short-term Investments (2016 - 2025)

United Therapeutics' Short-term Investments history spans 17 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Short-term Investments fell 13.16% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, down 13.16%, while the annual FY2025 figure was $1.4 billion, 13.16% down from the prior year.
  • Short-term Investments for Q4 2025 was $1.4 billion at United Therapeutics, down from $1.4 billion in the prior quarter.
  • Across five years, Short-term Investments topped out at $1.9 billion in Q4 2022 and bottomed at $899.0 million in Q1 2021.
  • The 5-year median for Short-term Investments is $1.5 billion (2022), against an average of $1.5 billion.
  • The largest annual shift saw Short-term Investments surged 81.24% in 2022 before it fell 19.47% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $1.0 billion in 2021, then soared by 81.24% to $1.9 billion in 2022, then decreased by 4.85% to $1.8 billion in 2023, then dropped by 12.12% to $1.6 billion in 2024, then dropped by 13.16% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Short-term Investments are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.5 billion (Q2 2025).